My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Piracetam (UCB-6215)
    Piracetam (UCB-6215)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1094
    CAS #: 7491-74-9Purity ≥98%

    Description: Piracetam (BRN-1526393; UCB-6215; Cl-871; Breinox; Ciclofalina; Euvifor; Gabacet; Nootron) is a cyclized derivative of the neurotransmitter gamma-aminobutyric acid (GABA) that has been approved for use in the treatment of a wide range of cognitive disorders. Piracetam is considered to be both a nootropic and a neuroprotective agent. Piracetam is a positive allosteric modulator of the AMPA receptor. It is believed to act on ion channels or ion carriers, thus leading to increased neuron excitability. 

    References: Biochim Biophys Acta. 2003 Jan 10;1609(1):28-38; Biochem Pharmacol. 1997 Jan 24;53(2):135-40.

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)142.16
    CAS No.7491-74-9
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 72 mg/mL (506.5 mM)
    Water: 72 mg/mL (506.5 mM)
    Ethanol: <1 mg/mL
    Other info

    Chemical Name: 1-Acetamido-2-pyrrolidinone


    InChi Code: InChI=1S/C6H10N2O2/c1-5(9)7-8-4-2-3-6(8)10/h2-4H2,1H3,(H,7,9)

    SMILES Code: O=C1N(NC(C)=O)CCC1

    SynonymsUCB-6215; Piracetam; Breinox; BRN-1526393; UCB6215; UCB 6215; BRN1526393; Ciclofalina; Cl871; BRN 1526393; Cl-871; Cl 871; EINECS 231-312-7; Euvifor; Gabacet; Genogris; Nootron; Nootropil; Nootropyl; Normabrain.

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: Piracetam is able to significantly decrease the fusogenic and destabilising effect of Abeta 29-42, in a concentration-dependent manner. Preincubation of piracetam, at a piracetam/peptide ratio of 960, during 20 min before the addition of Abeta 29-42 prevents almost completely the mixture of the two fluorescent probes. Preincubation of piracetam with lipids prevents almost completely the release of calcein induced by the peptide in a dose-dependent fashion (piracetam/peptide ratios from 9.6 to 960). Piracetam (< 1.0 mM) preincubated with brain membranes enhances membrane fluidity in aged mice, rats and humans, as indicated by decreased anisotropy of the membrane-bound fluorescence probe 1,6-diphenyl-1,3,5-hexatriene (DPH).

    In VivoPiracetam (300 mg/kg once daily) significantly increases membrane fluidity in some brain regions of young and aged rats, but has no measurable effect on membrane fluidity in the young rats. Piracetam (300 mg/kg daily for 6 weeks) improves active avoidance learning in the aged rats only and elevates membrane fluidity in all brain regions except the cerebellum in the aged rats. Piracetam (300 mg/kg daily for 6 weeks) also improves NMDA receptor density in the hippocampus and on muscarinic cholinergic receptor densities in the frontal cortex and the striatum and to a lesser extent in the hippocampus of rats. Piracetam (500 mg/kg p.o. for 14 days) elevates N-methyl-D-aspartate (NMDA) receptor density by about 20% and normalizes the enhanced affinity of L-glutamate for the NMDA receptor in aged mice. Piracetam-treated withdrawn rats has higher the number of synapses than that observed in nonpiracetam-treated and alcohol-fed animals by up to 20%, the mechanisms leading to the synaptic reorganization took place at the mossy fiber level.
    Animal modelMale Wistar rats 
    Formulation & DosageDissolved in saline; 300 mg/kg; oral gavage 

    Biochem Pharmacol. 1997 Jan 24;53(2):135-40; Pharmacopsychiatry. 1999 Mar;32 Suppl 1:10-6; Pharmacology. 1993 Oct;47(4):217-22.

    These protocols are for reference only. InvivoChem does not independently validate these methods.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?